http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012117334-A8

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d1861cdebdaaa4fe23aac04fb34268e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cfde6d96767761b6f12c5e0be68b8f46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9f43bd4b899662671f3792fae7725ac9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e497679c274f40034ad2cf945b0bf5d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b6ca95faa6e61de5a74e8207b118154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec2cf2772a722c89d7cdeaf3f7f441cc
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4035
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
filingDate 2012-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3513d17cf802eb2a451ef0524da40f2d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfa402f2a2be9726275102e79c6e00cb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16a813c2949f67a4ef31658f9ceba0f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09fada258be596bdcc7ea53c1841d6a2
publicationDate 2013-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2012117334-A8
titleOfInvention Mglur5 positive allosteric modulators for use in the treatment of phelan-mcdermid syndrome
abstract The invention concerns a novel therapeutic application for positive allosteric modulators of the metabotropic glutamate receptor mGluR5, notably for the therapeutic treatment of Phelan-McDermid syndrome caused by 22qI3 deletion. For this purpose, a preferred positive allosteric modulator is 3-cyano- N -(1,3-diphenyl-1-H-pyrazol-5-yl)benzamide, abbreviated as CDPPB.
priorityDate 2011-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID152743157
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419498216

Total number of triples: 29.